Sulfonylurea Stimulation of Insulin Secretion

  1. Peter Proks1,
  2. Frank Reimann2,
  3. Nick Green1,
  4. Fiona Gribble2 and
  5. Frances Ashcroft1
  1. 1University Laboratory of Physiology, Oxford University, Oxford, U.K
  2. 2Department of Clinical Biochemistry, University of Cambridge, Addenbrooke’s Hospital, Cambridge, U.K


    Sulfonylureas are widely used to treat type 2 diabetes because they stimulate insulin secretion from pancreatic β-cells. They primarily act by binding to the SUR subunit of the ATP-sensitive potassium (KATP) channel and inducing channel closure. However, the channel is still able to open to a limited extent when the drug is bound, so that high-affinity sulfonylurea inhibition is not complete, even at saturating drug concentrations. KATP channels are also found in cardiac, skeletal, and smooth muscle, but in these tissues are composed of different SUR subunits that confer different drug sensitivities. Thus tolbutamide and gliclazide block channels containing SUR1 (β-cell type), but not SUR2 (cardiac, smooth muscle types), whereas glibenclamide, glimepiride, repaglinide, and meglitinide block both types of channels. This difference has been exploited to determine residues contributing to the sulfonylurea-binding site. Sulfonylurea block is decreased by mutations or agents (e.g., phosphatidylinositol bisphosphate) that increase KATP channel open probability. We now propose a kinetic model that explains this effect in terms of changes in the channel open probability and in the transduction between the drug-binding site and the channel gate. We also clarify the mechanism by which MgADP produces an apparent increase of sulfonylurea efficacy on channels containing SUR1 (but not SUR2).

    Sulfonylureas stimulate insulin secretion from pancreatic β-cells and are widely used to treat type 2 diabetes. Their principal target is the ATP-sensitive potassium (KATP) channel, which plays a major role in controlling the β-cell membrane potential. Inhibition of KATP channels by glucose or sulfonylureas causes depolarization of the β-cell membrane; in turn, this triggers the opening of voltage-gated Ca2+ channels, eliciting Ca2+ influx and a rise in intracellular Ca2+ which stimulates the exocytosis of insulin-containing secretory granules (1). KATP channels are also found at high density in a variety of other cell types, including cardiac, smooth, and skeletal muscle, and some brain neurones. In all these tissues, opening of KATP channels in response to metabolic stress leads to inhibition of electrical activity. Thus they are involved in the response to both cardiac and cerebral ischemia (2). They are also important in neuronal regulation of glucose homeostasis (3), seizure protection (4), and the control of vascular smooth muscle tone (and, thereby, blood pressure) (5).

    The KATP channel is a hetero-octameric complex of two different types of protein subunits: an inwardly rectifying K+ channel, Kir6.x, and a sulfonylurea receptor, SUR (6,7). Kir6.x belongs to the family of inwardly rectifying K+ (Kir) channels and assembles as a tetramer to form the channel pore (Fig. 1A). Binding of ATP to the intracellular domains of this subunit produces channel inhibition (8). SUR is a member of the ABC transporter family, with 17 transmembrane helices (TMs), arranged as one group of 5 TMs, and two repeats each of 6 TMs followed by a large cytosolic loop containing consensus sequences for nucleotide binding and hydrolysis. Interaction of Mg nucleotides with the nucleotide-binding domains (NBDs) mediates activation of the KATP channel (912). SUR also endows Kir6.2 with sensitivity to certain drugs, such as the inhibitory sulfonylureas and the stimulatory K+ channel openers (6,7).

    More than one isoform exists for both Kir6.x (Kir6.1, Kir6.2) and SUR (SUR1, SUR2A, SUR2B). In most tissues, Kir6.2 serves as the pore-forming subunit, but it associates with different SUR subunits; for example, it associates with SUR1 in the pancreas and brain; SUR2A in heart and skeletal muscle; and SUR2B in brain and smooth muscle (1315). In vascular smooth muscle, the KATP channel is composed of Kir6.1 in association with SUR2B. Variation in the subunit composition of the KATP channel accounts for the different metabolic and drug sensitivities of KATP channels in different cells.

    Inhibitors of KATP channel activity fall into two groups: those that interact with Kir6.2 and those that interact with SUR. Imidazolines (e.g., phentolamine, cibenzoline) and antimalarials (e.g., quinine, mefloquine) block KATP channels by binding to Kir6.2 (1618). In contrast, sulfonylureas (e.g., tolbutamide, gliclazide, glimepiride), and benzamido derivatives (e.g., meglitinide) close KATP channels by binding with high affinity to SUR (1921). Sulfonylureas also interact with Kir6.2, but with low affinity. All drugs that block KATP channels stimulate insulin secretion, but only those that interact with the SUR subunit are used therapeutically to treat type 2 diabetes. Thus, in this review, we focus on how studies of recombinant KATP channels have helped to elucidate the molecular mechanism of sulfonylurea inhibition.


    When measured in excised patches in the absence of nucleotides, sulfonylurea block of KATP channels is best described by a two-site model (Fig. 1B). The low-affinity site is independent of SUR, as a similar block is seen when Kir6.2 is expressed in the absence of SUR (20). The high-affinity site lies on SUR, as it is only present when SUR is coexpressed with Kir6.2. The presence of both low- and high-affinity sites for sulfonylureas on the KATP channel introduces important considerations when interpreting experiments with these drugs. First, at high concentrations these drugs may mediate their effects via Kir6.2, and channel inhibition therefore cannot be taken to support the idea that they interact with the sulfonylurea receptor. Second, as discussed below, different SURs endow the KATP channel with variable sensitivity to low concentrations of sulfonylureas, a property that can be used to distinguish the type of sulfonylurea receptor expressed in different tissues. Finally, to isolate effects mediated by the high-affinity site, it is best to use a drug that shows a wide separation between its low- and high-affinity actions, such as gliclazide or glibenclamide. The low-affinity site is of no clinical relevance, because the concentrations required to inhibit the Kir6.2 subunit are much higher than those found in the plasma of patients treated with the drugs. Thus, in this review, we focus on the high-affinity drug-binding site.


    Because four SUR subunits contribute to the KATP channel complex, the question arises as to how many subunits must bind drug to close the channel. This topic is currently controversial. Dörschner et al. (22) found that the affinity of sulfonylurea binding to Kir6.2/SUR1 or Kir6.2/SUR2B channels is between three- and sevenfold lower than their potency on channel inhibition (Table 1). Consequently, they concluded that occupation of a single binding site is sufficient to induce channel closure. In contrast, Russ et al. (23) found that the concentration-response relation for [3H]glibenclamide binding to Kir6.1/SUR2B lies to the left of that for glibenclamide block of channel activity, so that the Kd is sevenfold lower than the half-maximal inhibitory concentration on channel activity (IC50) (Table 1). They therefore suggested that glibenclamide can bind independently to four identical sites on the channel and that occupation of all four sites is required for channel closure (23). Interestingly, the different proposed stoichiometries arise from the different binding affinities measured by these groups (Table 1). It is not clear why the affinities were found to be so different, but possible confounding factors include the nature of the Kir6.x subunit (Kir6.2 or Kir6.1) and the nucleotide concentrations used. The conflicting results suggest that conclusions based on comparing binding affinities with potencies of channel inhibition may not be reliable.


    In the absence of added nucleotides, high-affinity inhibition of the KATP current by sulfonylureas is not complete, but reaches a maximum of 60–80% (Fig. 1B). There are several possible explanations for this finding. One possibility is that some percentage of the channels are in a state in which they do not bind drug with high affinity. An alternative possibility is that all channels bind drug with high affinity, but they are still able to open when drug is bound, albeit with lower probability. Single-channel currents recorded at sulfonylurea concentrations that saturate the high-affinity site (but do not interact with Kir6.2) can be used to distinguish between these possibilities. If some channels exist in a low-affinity state and others in a high-affinity state, and transitions between these states are relatively slow, there should be two kinetically distinct populations of channels—one with a reduced open probability (PO) and another with kinetics similar to that observed in the absence of drug. On the other hand, if the reason for incomplete block by sulfonylureas is because the channel can still open when the drug is bound at the high-affinity site(s), then there will be only one type of single-channel kinetics. Under experimental conditions, only a single type of kinetic behavior has been observed in the presence of sulfonylureas (24; P.P., F.M.A., unpublished observations), supporting the idea that the channel can still open when drug is bound. Because it is thought that each SUR1 monomer binds drug independently, all four binding sites should be occupied at saturating drug concentrations. Thus it appears that the KATP channel can still open, even when each of its four SUR subunits has bound sulfonylurea.

    The maximal extent of block at the high-affinity site can be modulated by mutations or truncations in either Kir6.2 or SUR (2528), or by membrane phospholipids such as phosphatidylinositol bisphosphate (PIP2) (29). All these modulators share the common property that they increase the channel PO (2527,30,31). We therefore simulated the effect of PO on sulfonylurea block using the kinetic scheme given in Fig. 2B and rate constants calculated from single Kir6.2/SUR1 channel kinetics recorded in the absence and presence of gliclazide.

    As Fig. 2A shows, KATP channels exhibit bursts of openings separated by long closed periods. Gliclazide reduces the duration of the bursts of openings and increases the long closed intervals. The burst can be described by one open (O) and one short closed (C1) state, and the long closings between bursts can be lumped together into a single long closed state (C2). We assume that all these states can bind sulfonylurea, so that the channel can exist in both open and closed states when sulfonylurea is bound. We further assume that when drug is bound to SUR1, this either has no effect on channel activity (bound but untransduced states) or results in a conformational change that affects the channel kinetics (bound and transduced states). In the former case, the channel flickers between states OB, C1B, and C2B with the same rate constants as in the absence of drug. In the second case, the channel undergoes a conformational change that either results in channel closure (the OB to CT transition) or stabilization of the closed state (C2B to C2T). We made the simplifying assumption that the major contribution to the channel PO in the presence of sulfonylurea is produced by states with only a single drug molecule bound (i.e., only one SUR in the tetramer is occupied).

    This model explains the incomplete block by sulfonylureas, because, even when drug is bound, the channel does not inevitably enter the closed states C2B and CT. Entry into these closed states is not, therefore, directly proportional to the drug concentration, and channel opening is still possible, even at very high concentrations of the drug.

    The concentration-response curve for the high-affinity site is described by the following: Formula where G is the conductance in the presence of the drug, Gc is the conductance in the absence of drug, L is the fraction of current that remains unblocked in the presence of a saturating concentration of sulfonylurea, h is the Hill coefficient, and IC50 is the drug concentration ([S]) at which the fraction of the current inhibitable with high affinity is blocked by 50%. The kinetic scheme depicted in Fig. 2B allowed us to derive analytical equations that could be used to calculate the relation between the channel PO and L (Fig. 2C), and between PO and IC50 (Fig. 2D). It is clear that both L and IC50 increase with PO. The value of L reaches unity when the PO is maximal, which, in the case of the KATP channel, is ∼0.85, so that the model predicts that there will be no channel inhibition when PO is maximal. This has in fact been observed for channels containing the mutation C166S, which have a PO close to maximum (27). As predicted, reducing the PO of Kir6.2-C166S/SUR1 channels with ATP partially restored sulfonylurea sensitivity (25). The predicted effect of PO on the concentration-response curve is illustrated in Fig. 2E, and resembles that found experimentally with increasing concentrations of PIP2, which also increases PO (29).

    Deletion of the NH2-terminus of Kir6.2 (Kir6.2ΔN) results in an increase in the channel PO and a concomitant reduction in tolbutamide block when Kir6.2ΔN is co-expressed with SUR1 (25). The reduction in block produced by deletion of up to nine residues can be accounted for simply by the increase in PO. However, deletion of the first fourteen NH2-terminal residues produced a complete loss of tolbutamide inhibition, an observation that cannot be explained solely by an increase in PO. In addition, decreasing PO with ATP was unable to restore the tolbutamide sensitivity of this deletion mutant (25). Thus it appears that NH2-terminal residues may be involved in transducing sulfonylurea binding to SUR1 into closure of the Kir6.2 pore.


    Studies of cloned channels have revealed that certain KATP channel inhibitors (tolbutamide, gliclazide, and mitiglinide) (1921,32,33) block KATP channels containing SUR1, but not SUR2A or SUR2B, subunits with high affinity. In contrast, meglitinide blocks all three types of cloned KATP channel with similar affinities (21). This finding has been interpreted to indicate that sulfonylureas resembling tolbutamide in structure interact with a binding site that is specific to SUR1, whereas benzamido compounds and their derivatives (like meglitinide) interact with a site that is common to all SUR subtypes. Glibenclamide and glimepiride, which contain both sulfonylurea and nonsulfonylurea moieties and block both SUR1- and SUR2-containing channels, are postulated to interact with both sites on SUR1, but only a single (benzamido-derivative) site on SUR2 (21,34). The binding affinities and inhibitory potencies of these drugs for the high-affinity sites of different types of KATP channels are illustrated in Table 1.


    A single residue within the COOH-terminal set of transmembrane domains accounts for the difference in tolbutamide sensitivity of SUR1- and SUR2-containing channels. Mutation of serine 1237 in the cytoplasmic loop between TMs 15 and 16 to tyrosine abolishes the high-affinity block of Kir6.2/SUR1 channels by tolbutamide (35), mitiglinide (33), and nateglinide (55). It is likely that this residue also interacts with the sulfonylurea moiety of drugs such as glibenclamide and glimepiride. This is suggested by the fact that glibenclamide block of Kir6.2/SUR1, or native β-cell KATP channels, is not easily reversed in electrophysiological recordings, whereas glibenclamide block is rapidly reversed when SUR1 contains the S1237Y mutation. Kir6.2/SUR2 channels, which already possess a tyrosine at this position, also show reversible block by glibenclamide and glimepiride. In addition, glibenclamide binding to SUR1 is greatly decreased by the S1237Y mutation (35), whereas glibenclamide binding to SUR2B is enhanced by the reverse mutation (36,37). Thus S1237 must contribute to the binding site for sulfonylureas on SUR1. It is possible that the bulkier volume of the tyrosine side chain, as compared to serine, sterically hinders the binding of the sulfonylurea moiety, thereby accounting for its inability to interact with SUR2.

    The fact that glibenclamide blocks Kir6.2/SUR1-S1237Y channels indicates that residues other than S1237 are critical for binding of this drug. Likewise, the block of Kir6.2/SUR1 by meglitinide and repaglinide, which do not possess a sulfonylurea moiety, is unaltered by the S1237Y mutation (35,53), suggesting that these drugs do not interact with this residue. Recent studies have shown that two nonadjacent cytosolic loops of SUR1, linking TMs 5 and 6 and TMs 15 and 16, are critical for [3H]glibenclamide binding (38). Because the TM 15–16 loop contains S1237, this raises the possibility that the TM 5–6 loop may interact with benzamido compounds and their derivatives. Interestingly, the drug-binding site of the related ABC transporter MRP1 also involves sites in both NH2- and COOH-terminal parts of the protein, and the TM 5–6 loop is essential for high-affinity drug binding (39).

    These data do not imply that only residue S1237 in the TM 15–16 loop and unidentified residues in the TM 5–6 loop interact with sulfonylureas. However, it is clear that these residues are critical for high-affinity interactions. This suggests that despite their separate location in the primary structure of SUR, the cytosolic loops between TMs 5–6 and TMs 15–16 lie in close proximity in the three-dimensional structure of the channel. The maximal distance between them must be the length of the glibenclamide molecule (17 Å), but because the molecule is very flexible, they could be much closer. The location of the sulfonylurea binding site(s) within the cytosolic loops of SUR is consistent with earlier studies suggesting an intracellular site of action for sulfonylureas (40).


    It is well established that the sulfonylurea receptor can modulate the activity of Kir6.2, because binding of sulfonylureas or MgADP to SUR results in a decrease or increase of channel activity, respectively. There is growing evidence that Kir6.x can also affect the properties of SUR. Co-expression of Kir6.1 with SUR2A, or mutant SUR2B, has been shown to increase the affinity of [3H]glibenclamide binding by fivefold and fourfold, respectively (23,36). An even greater increase in affinity (eightfold) was found when Kir6.2 was co-expressed with mutant SUR2B (36). Coexpression of Kir6.2 with SUR1 has variously been reported to increase the affinity of [3H]glibenclamide binding (32) and to not affect it (22,41). Interestingly, Dörschner and colleagues (22) found no change in the [3H]glibenclamide binding affinity of SUR1 or SUR2 on co-expression with Kir6.x. These discrepancies may be a result of the different experimental conditions used by the groups or different fractions of uncoupled SUR subunits in the presence of Kir6.x. It is clear that additional experiments are needed to resolve this controversy.


    The phospholipid PIP2 reduces the maximal block produced by saturating concentrations of tolbutamide (28) and glibenclamide (29). It also increases the IC50 of the drug-sensitive fraction of channels. The effects of PIP2 are attenuated by the mutation R176A in Kir6.2 (29), which is believed to reduce PIP2 binding to this subunit. Furthermore, negatively charged lipids reduce glibenclamide block with similar potency, whereas neutral or weakly charged lipids have no effect. As described above, the effects of PIP2 on sulfonylurea sensitivity can be largely accounted for by the increase in channel PO produced by the phospholipid. However, it is also possible that PIP2 (like the NH2-terminal deletions) has additional effects on sulfonylurea block that are masked by the effect on the channel PO.

    The amount of PIP2 in the membrane can vary as a result of altered phospholipid metabolism. Thus PIP2 is expected to fall in response to ischemia (because falling ATP levels reduce its generation from PIP by phosphorylation) and increase when phosphatidylinositol kinases are stimulated. This means that PIP2 regulation of glibenclamide block will also be subject to regulation.


    As Fig. 1B shows, in the excised patch, the concentration-response curve for KATP channel inhibition by sulfonylureas is best fit by assuming both high- and low-affinity sites, with a maximum of 60–70% block at the high-affinity site. This is not the case when sulfonylurea block is measured in whole cells. Remarkably, sulfonylureas produce complete (>90%) high-affinity inhibition of both the native β-cell KATP channel (42,43) and its cloned counterpart, Kir6.2/SUR1 (44), when measured in the whole-cell configuration. This difference may arise because experiments on recombinant KATP channels have largely been carried out in excised patches, whereas experiments on native KATP channels have mainly been carried out in whole cells. We therefore compared the concentration-response curve for gliclazide block of Kir6.2/SUR1 currents in the intact cell with that in the inside-out patch.

    Figure 3A and B shows that there was no significant difference in the gliclazide concentration producing half-maximal block of Kir6.2/SUR1 channels or native β-cell KATP channels when measured in the whole cell (108 ± 3 and 184 ± 30 nmol/l, respectively), and the maximum block was similar, being >90% in both cases. In contrast, there was a marked difference in the maximal extent of gliclazide block of Kir6.2/SUR1 currents when measured in the intact cell and in the excised patch, which amounted to 93 and 60%, respectively.

    One explanation for the difference in the shape of the concentration-response curve in excised patches and whole cells is that it results from the presence of intracellular MgADP, which is always present in the intact cell, but not, unless deliberately added, in excised patches. Intracellular MgADP has been shown to produce an apparent increase in the efficacy of tolbutamide inhibition in both native and recombinant β-cell KATP channels (20,44,45). Gliclazide block of Kir6.2/SUR1 currents in inside-out patches was also much greater in the presence of 100 μmol/l MgADP (Fig. 3C), and the concentration-inhibition relation was best fit with a single-site model with an IC50 of 204 ± 7 nmol/l (n = 5). This finding was consistent with the idea that the difference in the maximal block mediated via the high-affinity site in excised patch and whole-cell recordings results from the presence of MgADP in the intact cell.

    MgADP has both stimulatory and inhibitory effects on the KATP channel, mediated by the SUR and Kir6.2 subunits, respectively (8). It has previously been hypothesized that the nucleotide produces an apparent enhancement of sulfonylurea block of Kir6.2/SUR1 currents, because the drug abolishes the stimulatory action of MgADP, while leaving the inhibitory effect untouched (20). Consequently, the combined inhibitory effects of sulfonylurea and nucleotide result in an enhanced inhibition. If this idea is correct, then gliclazide block of mutant KATP channels that show reduced nucleotide inhibition should be unaffected by MgADP.

    Mutation of the arginine at position 50 of Kir6.2 to glycine (Kir6.2-R50G) strongly reduces nucleotide block at the inhibitory site on Kir6.2 (46). The extent of this reduction can be quantified by examining the effect of ADP in the absence of Mg2+, because, in Mg-free solution, the stimulatory effect of ADP is abolished and the inhibitory effect of ADP is unmasked (20). As Fig. 4A shows, when tested in the absence of Mg2+, ADP potently blocked Kir6.2/SUR1 currents, but blocked Kir6.2-R50G/SUR1 currents much less effectively (<15%). As a result of this reduction in nucleotide block, ADP produced an enhanced stimulation of Kir6.2-R50G/SUR1 currents (compared with control currents) when applied in the presence of Mg2+.

    In the absence of nucleotides, the extent of gliclazide block of Kir6.2-R50G/SUR1 was similar to that found for the wild-type channel, whether measured in the presence or absence of Mg2+ (Fig. 4B and C). Thus the R50G mutation did not interfere with the action of the drug. However, although MgADP enhanced gliclazide block of wild-type channels, this was not the case for Kir6.2-R50G/SUR1 channels; indeed, the currents were actually slightly larger in the presence of the drug (Fig. 4B). These data support the idea that gliclazide reduces the stimulatory action of MgADP on wild-type channels and unmasks the inhibitory effect of the nucleotide. The fact that Kir6.2-R50G/SUR1 currents are somewhat greater in the presence of both drug and MgADP than in the presence of gliclazide alone suggests that 10 μmol/l gliclazide markedly reduces, but does not totally abolish, the stimulatory action of the nucleotide. An alternative explanation is that MgADP reduces the potency of gliclazide block, as 10 μmol/l gliclazide would not then saturate the high-affinity site.

    If gliclazide prevents the stimulatory action of MgADP, and unmasks its inhibitory effect, then the combined block by gliclazide and ADP on wild-type channels should be similar in the absence and presence of Mg2+. This was in fact observed (Fig. 4B and C). When Mg2+ was absent, Kir6.2-R50G/SUR1 currents were of similar amplitude in the presence of gliclazide or gliclazide plus ADP (Fig. 4C). This is presumably because ADP did not cause substantial block of the mutant channel. Because MgATP is the predominant Mg nucleotide in vivo, we also examined the effect of gliclazide on MgATP activation. Kir6.2-R50G/SUR1 currents were activated by MgATP (Fig. 4A), because the inhibitory effect of the nucleotide was impaired by the R50G mutation (10). As with ADP, the stimulatory action of ATP in the presence of Mg2+ was abolished by gliclazide (Fig. 4B).

    The potency of gliclazide block was significantly different when measured in the absence and presence of 100 μmol/l MgADP in excised patches (IC50 of 50 and 204 nmol/l, respectively). It is therefore possible that MgADP caused a small reduction in drug potency. This might also explain why gliclazide was somewhat less potent in intact oocytes (108 nmol/l). It also would be consistent with the fact that gliclazide block of Kir6.2-R50G/SUR1 currents is less in the presence of MgADP than in its absence. Although the effects of Mg nucleotides on gliclazide binding have not been investigated, it is known that [3H]glibenclamide binding to native β-cell KATP channels is decreased by MgADP (47). It is not clear whether gliclazide displaces MgADP from the nucleotide-binding domains of SUR1, or if it uncouples MgADP binding from channel activation. However, glibenclamide has been shown to cause unbinding of 8-azido-[32P]ATP to NBD1 of SUR1 in the presence of MgADP (48), lending some support to the former hypothesis.


    Binding of sulfonylureas to the cytoplasmic domains of SUR1 ultimately results in closure of the pore formed by Kir6.2. Precisely how this transduction occurs is unknown. There must be a close physical association between the glibenclamide binding site on SUR and the Kir6.2 subunit, as both proteins can be photoaffinity labeled by [125I]glibenclamide (7). Five residues within the first TM of Kir6.2 are essential for interaction with SUR (49), and recent studies have indicated that the first five TMs of SUR1 are also involved (50). However, although these regions are required for structural interactions, it is not clear whether they are also involved in functional coupling. Mutagenesis studies, however, have implicated the NH2-terminus of Kir6.2 and the COOH-terminus of SUR1 in coupling sulfonylurea binding to channel inhibition (25,26).


    Sulfonylureas have been used for many years to treat type 2 diabetes, but it is only now that the details of their molecular mechanism of action are beginning to be unraveled. As first proposed by Henquin and colleagues (51), antidiabetogenic sulfonylureas, benzamido compounds, and their derivatives appear to interact with more than one part of the KATP channel. This suggests that, like other ATP-binding cassette transporters, SUR possesses a large multifaceted drug-binding pocket that can accommodate several structurally distinct compounds. Individual compounds differ in the residues within this pocket with which they interact. Studies of recombinant KATP channels suggest that the sulfonylurea moiety interacts with residues in the TM 15–16 linker of SUR1, whereas benzamido derivatives may interact with the TM 5–6 linker in the NH2-terminal part of the protein. How these different parts of the sulfonylurea receptor contribute to drug binding, and how this is transduced into changes in channel activity, remains far from clear and awaits determination of the structure of SUR, and its relation to Kir6.2, at atomic resolution.

    Currently, sulfonylureas are classified as first- and second-generation drugs, although there is no structural or functional basis for this classification. We now know that some sulfonylureas bind with high-affinity to SUR1, but not SUR2, whereas others interact with both types of SUR. We therefore propose that the classification of sulfonylureas, meglitinide derivatives, and structurally related compounds be changed to reflect the functional differences among these drugs, and that they be referred to instead as SUR1-specific and non-SUR1-specific.

    FIG. 1.

    A: Schematic of the transmembrane topology of Kir6.2 and SUR1. B: Mean relation between gliclazide concentration and inhibition of the Kir6.2/SUR1 current, measured in inside-out patches (n = 5–8). The conductance in the presence of gliclazide (G) is expressed as a fraction of its amplitude in the absence of the drug (Gc). The line is fit to (equation 2) G/Gc = (L + (1 − L)/(1 + ([S]/IC50–1)h1)) × (1/(1 + ([S]/IC50–2)h2)), where IC50–1 = 51 nmol/l, h1 = 1.0, IC50–2 = 3.1 mmol/l, h2 = 1, and L = 0.40 (19); [S] is the concentration of sulphonylurea; IC50–1 and IC50–2 are the half-maximal inhibitory concentrations at the high- and low-affinity sites, respectively; h1 and h2 are the Hill coefficients for the high- and low-affinity sites, respectively; and L is the fraction of current that remains unblocked when all high-affinity sites are occupied.

    FIG. 2.

    A: Single-channel currents recorded at −60 mV in the absence (top) or presence (bottom) of a saturating concentration of gliclazide (10 μmol/l). B: Kinetic scheme for KATP channel gating in the presence of sulfonylureas. Agents that increase PO usually mediate their effects by increasing the burst duration and reducing the frequency of the interburst closed states (i.e., they reduce k2). The relation between k2, PO, and IC50 was derived as described previously (27). When drug is bound but untransduced, the channel can exist in states OB, C1B, or C2B. The closed states that result following the conformational change permitted by drug binding are given by CT and CT2. O, open state; C1, intraburst closed state; C2, lumped interburst closed states; gray box, burst state. C and D: Relation between channel PO and the fraction of current that remains unblocked in the presence of a saturating concentration of sulfonylurea (L) (C) or IC50 (D). The PO in the presence of sulfonylurea predicted by the kinetic scheme in B is given by Formula where κ2 = k2/k-2; κ = kB/k-B; κTO = kTO/k−TO, and κTC = kTC/k-TC. Equating Pos/PO with I/IO leads to Formula where IC50 = 1/{κ × [1 + λ × (Pmax − PO)]}, Formula where ΔGC2T,CT = GC2T − GCT. For these plots, the values of λ and κ were obtained from the IC50 and L (0.4) measured for gliclazide block of Kir6.2/SUR1 currents (19), assuming a PO of 0.32 (25). IC50 = 50 nmol/l for the high-affinity site and 3 mmol/l for the low-affinity site. E: Relation between the inhibition of the KATP current and drug concentration at various values of PO, calculated using the kinetic scheme given in B and the equations in C and D. The low-affinity block is assumed to be unchanged by alterations in channel PO, as found experimentally (25). The curves are fit to equation 2.

    FIG. 3.

    A: Whole-cell KATP currents recorded using a two-electrode voltage clamp from an intact oocyte expressing Kir6.2/SUR1, in response to a series of depolarizing and hyperpolarizing 10-mV pulses from a holding potential of −10 mV. Azide (3 mmol/l) and gliclazide (1 mmol/l) were added to the extracellular solution, as indicated. Methods are the same as those described in ref. 42. B: Mean relation between gliclazide concentration and inhibition of the Kir6.2/SUR1 current, measured in the intact oocyte (n = 6). The current evoked by a voltage step to −100 mV in the presence of gliclazide (I) is expressed as a fraction of its amplitude in the absence of the drug (IO). The solid line is the best fit of equation 1 to the data, with IC50 = 108 ± 3 nmol/l (n = 5), h = 0.81, and L = 0. The dotted line shows the fit obtained for gliclazide block of Kir6.2/SUR1 currents in the excised patch configuration (see Fig. 1). The dashed line shows the fit obtained for gliclazide block of the native β-cell KATP channel in whole-cell recordings from mouse pancreatic β-cells (IC50 = 184 nmol/l) (42). C: Relation between gliclazide concentration and inhibition of the Kir6.2/SUR1 current, measured in the inside-out patch in the presence of 100 μmol/l MgADP (n = 5). The current evoked by a voltage step to −100 mV in the presence of gliclazide (I) is expressed as a fraction of its mean amplitude in the absence of the drug (IO). The solid line is the best fit of equation 1 to the data, with IC50 = 204 nmol/l, h = 1.13, and L = 0.065. The dashed line shows the fit obtained in the absence of added nucleotide (adapted from Gribble et al. [19]).

    FIG. 4.

    A: Mean Kir6.2/SUR1 or Kir6.2-R50G/SUR1 conductance in the presence of 100 μmol/l ADP (▪), 100 μmol/l ADP + 2 mmol/l Mg2+ (Graphic), or 100 μmol/l ATP plus 2 mmol/l Mg2+ ([cjs2112]). B and C: Mean Kir6.2/SUR1 or Kir6.2-R50G/SUR1 conductance in the presence of 10 μmol/l gliclazide (□), 10 μmol/l gliclazide plus 100 μmol/l ADP (Graphic), or 10 μmol/l gliclazide plus 100 μmol/l ATP ([cjs2112]), in the presence (B) or absence (C) of 2 mmol/l Mg2+. Conductance (G) is expressed as a fraction of that in the absence of the drug and nucleotide (Gc). The number of patches is given above each bar. The dashed line indicates the control conductance level.

    TABLE 1

    Comparison of the IC50 for KATP channel inhibition by various sulfonylureas with the Kd for drug binding


    We thank the Wellcome Trust and the Beit Memorial Trust for support. F.A. is the Royal Society GlaxoSmithKline Research Professor, P.P. is a Beit Memorial Trust Fellow, F.G. is Wellcome Trust Clinician Scientist Fellow, and F.R. is a Diabetes U.K. R.D. Lawrence Fellow.


    • Address correspondence and reprint requests to Prof. Frances M. Ashcroft, University Laboratory of Physiology, Parks Road, Oxford OX1 3PT, U.K. E-mail: frances.ashcroft{at}

      Received for publication 12 March 2002 and accepted in revised form 8 May 2002.

      IC50, half-maximal inhibitory concentration value; KATP channel, ATP-sensitive potassium channel; Kir channel, inwardly rectifying K+ channel; NBD, nucleotide-binding domain; PO, open probability; SUR, sulfonylurea receptor; TM, transmembrane helix.

      P.P., F.G., and F.A. receive honoraria from Servier for speaking engagements. F.A. is a paid consultant for NovoNordisk.

      The symposium and the publication of this article have been made possible by an unrestricted educational grant from Servier, Paris.


    No Related Web Pages
    | Table of Contents